… Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and U. … low cost-effectiveness of the drug used to treat dementia caused … to a system that adjusts drug prices based on cost- … high-priced or large-market drugs. [Copyright The Jiji Press, …

… bolstering its neurology ambitions, French pharmaceutical giant Sanofi has finalized its … . However, challenges loom. Alzheimer’s drug development has a notoriously high … current treatments, like Leqembi from Eisai and Biogen, offer modest benefits …

Nuvectis Pharma is terminating development of NXP800 … market across the seven major pharmaceutical markets (7MM: US, France, Germany … platinum resistance. This includes Eisai’s antibody-drug conjugate (ADC) farletuzumab ecteribulin …

… -AI) for lecanemab (Leqembi; Eisai), an approved medication for early … continued biweekly IV dosing. Eisai’s SC-AI formulation … low rate of validated anti-drug antibodies (ADA; 2%) with … et al. Clinical and Pharmacologic Profile of a Subcutaneous Lecanemab …

A newly presented interim report gave a snapshot of the real-world efficacy and safety of lecanemab (Leqembi; Eisai), a medication for early-stage Alzheimer disease (AD), at 2 years following its 2023 approval. While the study only included less than 200 …

… in contrasts for the pharmaceutical industry. Total drug sales largely rebounded as … . The cumulative prescription drug sales of the Top 20 pharma companies (ranked … , fixed-dose combos). Biogen and Eisai’s Alzheimer’s programs could …

… the pipeline landscape, pipeline drug profiles, including clinical … ., Pulmatrix, Eisai, GlaxoSmithKline, EpiEndo Pharmaceuticals, 3SBio, OmniSpirant, Foresee Pharmaceuticals, Amgen, Organicell … market trends, in emerging drugs, and competitive strategies. …

… Bristol Myers Squibb, Cerevel, Eisai, Ono Pharmaceuticals, Rocher Pharmaceuticals and UCB; and receiving … Idec, Cerevel, Eisai, Eli Lilly, Genentech, Jannsen Pharmaceuticals, Roche Pharmaceuticals and UCB. Please …

WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I'm Marco Meglio. Newly announced findings from the phase 2 RePOSA trial (NCT06146101) showed that IHL-42X (Incannex), an investigational therapy for obstructive sleep …

… (CDR-SB) scale, highlighting the drug’s capacity to stave off … patients who began taking the drug early, with early initiation offering … the period in which a drug can stave off disease progression … mAbs) such as Biogen & Eisai’s Leqembi (lecanemab) and Eli …